Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 14/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437671 | 0.83 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL1437637 | 0.81 | PSIP1 (0.56) | CYP3A4CYP2C9CYP2C19BRAFHSD17B10 | |
| SCHEMBL20399233 | 0.81 | FABP4 (0.51) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL1492027 | 0.81 | CYP2C9 (0.50) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL3019846 | 0.79 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19BRAFPSIP1 | |
| SCHEMBL14317717 | 0.79 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19BRAFPARP14 | |
| SCHEMBL14964586 | 0.78 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19BRAFPSIP1 | |
| SCHEMBL1492048 | 0.76 | CYP2C9 (0.48) | CYP3A4CYP2C9CYP2C19BRAFPSIP1 | |
| SCHEMBL14574987 | 0.74 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19BRAF | |
| SCHEMBL22833348 | 0.74 | CYP2C9 (0.47) | CYP3A4CYP2C9CYP2C19BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710055-B2 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012085127-A1 | NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322803-A1 | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors | CDK2, TNNI3K, CDK1 | CYP3A4 4045/4885CYP2C9 4366/4885CYP2C19 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.